There is a wide current development of blocking agents against different components of complement such as APL-2 (pegcetacoplan derivative of compstatin that blocks C3) or narsoplimab (that blocks MASP2) in lupus nephritis, and IFX-1 (that blocks C5a) in AAV [187]. This evidence concerns the gene C5 and lupus nephritis.